|
|
 |
|
Viewing report
|
|
|
|
Worldwide Prescription Drug Market for Womens Health: Now and Future 2004-2009
Fuji-Keizai USA, Inc., Feb 2005, Pages: 151
This report looks at the worldwide prescription drug market for women's health and estimates the market outlook to 2009. The research study shows that, while the global economy has had its ups and downs, this report projects that the market will grow to about $116 billion in 2009 and will grow at a rate of about 16.6% (CAGR).
Substantial unmet need exists in the women's health field and this report identifies the profitable marketing opportunities pharmaceutical companies can pursue by developing their businesses to include this market. In this report, we have identified diseases and conditions that particularly affect women at a rate of 55% or greater of the population of the industrialized world. As a result, women have some unique health needs. The women's broad range of healthcare needs makes them a more lucrative marketing target than men.
Readers receive detailed data and analysis about important worldwide pharmaceutical industry developments. The research report discusses the main therapeutic areas of women¹s diseases or conditions with a brief description of the disease; patient populations, incidence, prevalence and mortality; gives the drug market size by disease; market participants; current drug treatments and revenues; market trends; new Rx drug R&D pipeline and its potential year to launch.
Pharmaceutical and biotech industry executives, product managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The report discusses the numerous women's health pharmaceutical industry topics with interesting and useful findings. Over 37 tables and 15 figures illustrate the findings throughout this 'must have' study.
Detailed information about the business and R&D activities of the top pharmaceutical and biotechnology companies is listed in many areas of this report including more than 29 company profiles. Each profile includes financial data, current Rx drugs, 'female adjusted' revenue estimates by indication, late stage drugs in the pipeline and likely launch year.
Customers who bought this item also bought
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Womens Health Female Sexual Dysfunction
Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey
Stakeholder Opinions: Hepatocellular Carcinoma - Opportune Indication For Novel Therapies
Female Sexual Dysfunction Therapy Area Pipeline Report
Major Milestones: Female Sexual Dysfunction
Stakeholder Opinions: Ovarian Cancer Growing Importance as Secondary Indication for Targeted Therapies
Strategic Perspectives: Female Sexual Dysfunction - Are Physicians and Patients Ready For a Female Viagra?
Pipeline Insight: Osteoporosis - Intermittent Dosing Drives Market Growth
U.S. Sexual Dysfunction Medication Markets
|
|
|
|
